No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: No P/S history yet
Annual revenue · last 4 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:27:48.234Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T15:27:48.234Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T15:27:48.234Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for MiniMed Group, Inc. Common Stock (MMED) stock was $19.71 as of Oct 6, 2026, 11:25 AM EDT, down 2.23% from the previous close.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management.
Medical - Equipment & Services · Northridge, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-04-24 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-04-24 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$0.13
vs Estimate
$0.10
Revenue
$843.00M
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MMED | $5.54B | $19.71 | -2.23% | N/A | N/A | N/A | N/A |
| 2DOCS | $5.36B | $28.68 | +0.35% | -60.81% | -18.23% | N/A | vs MMED |
| 3KNSA | $5.78B | $75.91 | -0.53% | +97.61% | +47.48% | N/A | vs MMED |
| 4CRSP | $5.26B | $54.53 | -4.90% | -15.29% | -10.97% | N/A | vs MMED |
| 5COGT | $5.25B | $30.74 | -0.41% | +95.25% | +28.51% | N/A | vs MMED |
| 6CGON | $5.83B | $66.11 | -3.78% | +72.10% | N/A | N/A | vs MMED |
forward FY estimate
29.27
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
vs Estimate
$826.80M
Consensus Rating
Based on 12 analysts
Average Price Target
$24.92
+26.4% upside
Low
$15.00
Current
$19.71
High
$29.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $0.11 | $0.14 | $0.22 | 6 |
| Quarter ending Jan 2027 | $0.20 | $0.21 | $0.23 | 6 |
| Quarter ending Apr 2027 | $0.28 | $0.29 | $0.29 | 4 |
| Quarter ending Jul 2027 | $0.01 | $0.01 | $0.01 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $0.63 | $0.67 | $0.70 | 5 |
| FY 2028 | $0.43 | $0.65 | $0.75 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $817.93M | $825.14M | $836.31M | 7 |
| Quarter ending Jan 2027 | $857.63M | $861.22M | $868.44M | 7 |
| Quarter ending Apr 2027 | $899.47M | $905.88M | $913.94M | 4 |
| Quarter ending Jul 2027 | $881.54M | $887.82M | $895.72M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Apr 24, 2027, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $3.43B | $3.44B | $3.47B | 10 |
| FY 2028 | $3.66B | $3.71B | $3.78B | 10 |
